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36 
Abstract 37 
Increasing antibiotic resistance makes choosing antibiotics for suspected Gram-negative 38 
infection challenging.  This study set out to identify key determinants of mortality among 39 
patients with Gram-negative bacteraemia, focusing particularly on the importance of 40 
appropriate empiric antibiotic treatment.  41 
 42 
We conducted a prospective observational study of 679 unselected adults with Gram-negative 43 
bacteraemia at ten acute English hospitals between October 2013 and March 2014.  Appropriate 44 
empiric antibiotic treatment was defined as intravenous treatment, on the day of blood culture 45 
collection, with an antibiotic to which the cultured organism was sensitive in vitro.  Mortality 46 
analyses were adjusted for patient demographics, co-morbidities and illness severity. 47 
 48 
The majority of bacteraemias were community onset (70%); most were caused by Escherichia 49 
coli (65%), Klebsiella spp (15%) or Pseudomonas spp (7%).  Main foci of infection were urinary 50 
tract (51%), abdomen/biliary tract (20%) and lower respiratory tract (14%). The main 51 
antibiotics used were co-amoxiclav (32%) and piperacillin-tazobactam (30%) with 34% 52 
receiving combination therapy (predominantly aminoglycosides). Empiric treatment was 53 
inappropriate in 34%.  All-cause mortality was 8% at 7-days and 15% at 30-days.  Independent 54 
predictors of mortality (p<0.05) included older age, greater burden of co-morbid disease, 55 
severity of illness at presentation and inflammatory response. Inappropriate empiric antibiotic 56 
therapy was not associated with mortality at either time point (adjusted OR=0.82 (95% CI 0.35-57 
1.94) and 0.92 (0.50-1.66) respectively).  58 
 59 
Although our study does not exclude an impact of empiric antibiotic choice on survival in Gram-60 
negative bacteraemia, outcome is determined primarily by patient and disease factors. 61 
 62 
63 
INTRODUCTION  64 
Bacteraemia is a common and severe systemic infection which affects approximately 600,000 65 
people in the United States and 1.2 million people in Europe each year ; 15% of affected patients 66 
die within 30-days [1].  During the 1990s Gram-positive bacteria were the major pathogens 67 
causing bacteraemia but Gram-negative bacilli (GNB), particularly Enterobacteriaceae, are now 68 
re-emerging as the predominant pathogens isolated from blood [2-3]. 69 
 70 
Selection of appropriate empiric antibiotic treatment for suspected Gram-negative infection is 71 
particularly challenging because rates of resistance to the main antibiotic classes are increasing 72 
[4]; leading to enormous reliance on broad-spectrum agents [5].  The appropriateness of 73 
empiric antibiotic therapy for bacteraemia has been proposed as a performance measure for 74 
antimicrobial stewardship programmes [6.7]. However, the prognostic impact of empiric 75 
therapy in GNB bacteraemia is not established.  76 
 77 
The impact of empiric antibiotic treatment on clinical outcome has been studied predominantly 78 
in critically ill patients with severe sepsis and septic shock. Among such patients delays in 79 
initiating active antibiotic treatment have been linked to increased risk of death [8,9]. However, 80 
these results may not be generalisable to all sepsis patients in whom other studies report 81 
benefit from delayed, focused treatment (10,11). Furthermore only around 50% of patients 82 
recruited to severe sepsis studies are bacteraemic and many studies investigating the impact of 83 
empiric antibiotic therapy specifically in bacteraemia have methodological limitations such as 84 
small sample size, heterogeneous patient populations and retrospective design [12-24]. A 85 
systematic review of these studies a published in 2007 found ‘little evidence for or against 86 
recommendations regarding aggressive empiric therapy with broad-spectrum antibiotics’ [25]. 87 
Two subsequent large, prospective studies have produced contrasting results among different 88 
patient populations (26,27). However, <50% of cases had GNB bacteraemia in these studies. In a 89 
retrospective study specifically in GNB bacteraemia Cain et al found an effect of empiric 90 
antibiotic therapy only among patients with a high prior probability of death(28).  91 
The objective of this prospective, multi-centre observational cohort study was to identify the 92 
key determinants of mortality among unselected patients with GNB bacteraemia; focusing 93 
particularly on the importance of appropriate empiric antibiotic treatment.  94 
95 
PATIENTS AND METHODS 96 
Setting and study population 97 
We conducted this study at ten acute hospitals in England (see acknowledgements) including 98 
large (>1000 bed) tertiary hospitals and medium (500-1000 bed) district hospitals. Sites 99 
included cases for slightly different periods of 50-120 days depending on staff availability 100 
between November 2013 and March 2014, but at each site, while open medical microbiologists, 101 
recorded baseline clinical characteristics, management and outcome of consecutive adult 102 
patients fulfilling eligibility criteria at the time of routine clinical review.  The co-primary 103 
outcomes were mortality at 7 and 30 days after blood was taken for culture, confirmed through 104 
each hospital’s management information system which includes post-discharge deaths. 105 
Patients were eligible for inclusion if they were ≥18 years, had one or more blood cultures 106 
showing a pure growth of either a lactose fermenting coliform (E. coli, Klebsiella spp., 107 
Enterobacter spp., Serratia spp., Morganella spp., Citrobacter spp., or Proteus spp.) or a 108 
Pseudomonas spp.  Patients were excluded if the blood isolate was mixed with another pathogen.  109 
Only the first bacteraemia for each patient was included.  110 
Organisms were identified and antibiotic sensitivity testing performed according to standard 111 
methods by each hospital’s diagnostic laboratory. 112 
 113 
Definitions 114 
Bacteraemias were categorised as nosocomial if the first positive sample was taken ≥48 hours 115 
after hospital admission, otherwise they were categorised as community-acquired.  Additionally, 116 
if the patient had been admitted to hospital in the preceding 30 days, had been transferred from 117 
another healthcare facility, was receiving chronic dialysis, immunosuppressive medication or 118 
had metastatic cancer, bacteraemia were considered healthcare-associated community-119 
acquired. 120 
Burden of co-morbid disease was assessed using an age-adjusted Charlson score.  Severity of 121 
illness was assessed using the National Early Warning System (NEWS) Score which is widely 122 
used in English hospitals and assigns points for respiratory rate, oxygen saturation, need for 123 
supplemental oxygen, temperature, systolic blood pressure, heart rate and conscious level 124 
(range 0-21) [29]. Patients scoring ≥5 should receive urgent medical review and ≥7 should be 125 
considered for escalation to high-dependency or intensive care. 126 
Patients were considered to have received appropriate empiric antibiotic treatment if they were 127 
prescribed one or more intravenous doses of one or more antibiotics to which the organism 128 
cultured was sensitive in vitro on the day the blood culture was taken [13].  129 
 130 
Ethics 131 
Prior to the project starting the NHS Health Research Authority confirmed it constituted a 132 
service evaluation not requiring patient consent or formal review by a research ethics 133 
committee.  Local research and development office approval was secured at each site. 134 
 135 
Statistical analysis 136 
Continuous and categorical baseline factors were compared using Kruskal-Wallis and χ2 tests 137 
respectively. To account for vary amounts of missing data associations between baseline factors 138 
and 7- and 30-day mortality (binary outcome, logistic regression) were assessed univariably 139 
using both complete cases, and in multivariable models using 25 imputations with chained 140 
estimating equations [30] (see supplementary material for details).  As the key exposure was 141 
empiric antibiotic therapy, patients who died on the day blood was taken for culture were 142 
excluded from the primary imputations and multivariable analysis because antibiotics may be 143 
futile so close to death. A sensitivity analysis included these patients in imputations and 144 
multivariable analyses. Final multivariable models were selected using backwards elimination 145 
(exit p>0.05) retaining empiric therapy as the key exposure of interest and including other 146 
significant factors to ensure control of confounding. See supplementary material for further 147 
details, including calculation of adjusted absolute mortality percentages and post-hoc sample 148 
size calculation. Analyses were performed using SPSS (IBM: Version 22) and Stata 13.1. 149 
150 
RESULTS 151 
Study sites achieved a median of 96.5% recruitment of eligible patients (IQR 93.5-100%) 152 
obtaining prospective data on 679 adults with microbiologically confirmed GNB bacteraemia. 153 
Nine (1%) who died on the day blood was taken for culture were excluded from primary 154 
multivariable analyses, but included in sensitivity analyses. Data describing antimicrobial 155 
susceptibility or treatment were missing for 54 (8%) patients, leaving 616 (91%) with complete 156 
data on antibiotic treatment and 7-day mortality (figure 1). 30-day mortality data were missing 157 
on a further five. 158 
Overall mortality was 8% (52/679) and 15% (101/674) at 7 and 30-days respectively. Table 1 159 
shows the univariable associations between mortality and patient and disease factors and 160 
appropriateness of empiric antibiotic treatment for all 679 patients. In both complete-cases and 161 
multiple-imputations, patients who died within 7 days were older, had a greater burden of 162 
comorbid disease, were more acutely unwell as measured by NEWS score, more often had a 163 
non-urinary focus of infection and had higher levels of CRP and creatinine than patients who 164 
survived. Univariably Klebsiella and Pseudomonas spp. bacteraemia were also associated with 165 
higher 7-day mortality. The only additional factor consistently associated with higher 30-day 166 
mortality was nosocomial-onset bacteraemia. Among the 616 patients in whom appropriateness 167 
of empiric antibiotic therapy could be assessed, 210 (34%) received inappropriate treatment, 168 
106 (17%) because the regimen used was not active in vitro, 104 (17%) because although active 169 
in vitro it was not given intravenously on the day of culture. Rates of inappropriate treatment 170 
were similar in survivors and non-survivors in both complete-cases and multiple imputations at 171 
both day-7 and day-30 (p>0.2). 172 
Antibiotic resistance was most common to amoxicillin/ampicillin (64% for E. coli) and co-173 
amoxiclav (36% overall). The most commonly used antibiotics were co-amoxiclav (32%) and 174 
piperacillin-tazobactam (30%) either alone or in combination with a second agent, usually an 175 
aminoglycoside (supplementary table 1). 34% of patients received combination therapy and 176 
this increased the activity of treatment against the organism cultured when the combination 177 
was with co-amoxiclav (27% vs 2%; p<0.001) and piperacillin-tazobactam (15% vs 6%; 178 
p=0.05).  179 
As expected, significant potentially-confounding associations were present between patient, 180 
disease and treatment factors. Males were older (median (IQR) 73 (62-81) vs 71 (55-82) years 181 
p=0.03) and less likely to have E. coli bacteraemia (p<0.001). E. coli bacteraemias were less 182 
often nosocomial (24%), compared to Klebsiella spp. (40%), Pseudomonas spp (43%) and other 183 
Enterobacteriaceae (43%) (p<0.001).  The commonest focus for E. coli bacteraemia was the 184 
urinary tract (58%) whereas for other GNB non-urinary foci predominated (Klebsiella spp. 63%, 185 
Pseudomonas spp. 67%. and other Enterobacteriaceae 62%) (p<0.001). At the time blood was 186 
taken for culture, median NEWS score was 4 (IQR 2-7;27% ≥7, when high-dependency transfer 187 
should be considered). Patients with E. coli bacteraemia had slightly lower NEWS score than 188 
other patients (median 4 (IQR 2-6) vs 5 (2-7), p=0.05). Patients with a urinary tract or line-189 
related bacteraemia were less acutely unwell at presentation with 23% and 19% having NEWS 190 
≥7 respectively, compared with 53% of patients with lower respiratory tract infection 191 
(p=0.006). Among baseline laboratory tests, only C-reactive protein (CRP) varied significantly 192 
by causative organism (p<0.001); being higher in patients with Pseudomonas spp. bacteraemia 193 
(median 180mg/dL (IQR 81-269)  compared with 129mg/dL (IQR 58-202) for other 194 
bacteraemias (p=0.01).  There was no evidence that appropriateness of treatment varied across 195 
species (p=0.7). NEWS score was slightly higher overall in those who received appropriate 196 
antibiotics (median (IQR) 4 (3-7) vs 4 (2-6) in those who did not (p=0.02). Among 143 patients 197 
who had a NEWS score ≥7, 7-day mortality was 12/100 (12%) for patients who received 198 
appropriate treatment and 4/43 (9%) for patients who did not (p=0.7); 30-day mortality was  199 
23/113 (20%) versus 6/42 (14%) respectively (p=0.5).  200 
In multivariable analysis adjusting for these inter-relationships, older age, higher NEWS score 201 
and higher CRP independently predicted greater 7-day and 30-day mortality (Table 2).  In 202 
addition, patients with neutropenic sepsis were at increased risk of 7-day mortality. Higher 203 
Charlson score and neutrophil count, lower platelets, nosocomial onset, lower respiratory tract 204 
focus and onset of symptoms after blood cultures were taken also independently predicted a 205 
death at 30-days but not 7-days.  Inappropriate empiric antibiotic therapy was not associated 206 
with mortality at either time point (adjusted OR=0.82 (95% CI 0.35-1.94) and 0.92 (0.50-1.66) 207 
respectively).  There was no evidence of interactions between empiric therapy and other factors 208 
for 7-day or 30-day mortality (p>0.08) except for 30-day mortality and neutrophils (interaction 209 
p=0.03); whereby risk of mortality at 30 days was higher in those receiving appropriate 210 
antibiotics with higher neutrophils. To assess the possibility that excluding the nine patients 211 
who died on the day of culture had obscured a benefit of early empiric therapy, a sensitivity 212 
analysis included these patients (two received appropriate therapy, seven died before initiating 213 
antibiotics classed as inappropriate therapy; Supplementary Table 2). Inappropriate empiric 214 
antibiotic therapy was still not associated with mortality at either time point (adjusted OR=1.24 215 
(95% CI 0.62-2.49) and 1.15 (0.69-1.24) respectively). 216 
 217 
218 
DISCUSSION 219 
We have undertaken a detailed prospective observational study of patients with GNB 220 
bacteraemia assessing the importance of appropriate empiric antibiotic treatment adjusted for 221 
confounding from patient and disease factors. 8% of our patients died within 7-days and 15% 222 
within 30-days. 34% did not receive an intravenous antibiotic with in vitro activity against the 223 
infecting pathogen on the day of blood culture.  Mortality was not higher among these patients 224 
in any adjusted or unadjusted analysis using complete-cases or multiple-imputation. The main 225 
predictors of death were patient and disease factors, particularly older age, greater burden of 226 
disease, nosocomial acquisition and greater severity of acute illness.   227 
Our findings contrast with several studies performed in the 1990s which reported that the 228 
appropriateness of empiric therapy is a key determinant of outcome in bacteraemia (12-14). It 229 
is notable that in these studies the main factor responsible for treatment being inappropriate 230 
was delay, measured in days, rather than resistance. Prompt review and treatment adjustment 231 
24-48 hours after culture is standard practice in the NHS and may minimise the impact of 232 
inappropriate empiric therapy.  Other studies demonstrating an impact of empiric therapy in 233 
bacteraemia have been performed in populations where multidrug resistance is common 234 
(16,19,23,24) or have included both Gram-positive and Gram-negative infections, sometimes 235 
along with fungaemia (17-19,27). We have studied GNB bacteraemia specifically and in a setting 236 
where multidrug resistance is uncommon. It may be that in our study patients in the 237 
‘inappropriate’ group received therapy to which the organism was resistant in vitro but 238 
nevertheless had some activity in vivo.  This may be particularly relevant for co-amoxiclav 239 
where the break-point (≤8mg/L) used to define susceptibility for systemic infections lies within 240 
the distribution of MICs for E. coli and disc testing may over-estimate resistance compared with 241 
broth microdilution methods. Some studies have considered quinolones, if active in vitro and 242 
given promptly as appropriate therapy in GNB bacteraemia. However, only four patients 243 
received ciprofloxacin by mouth on the day of blood culture in our study for a ciprofloxacin 244 
sensitive infection and re-categorising these cases does not alter our findings (data not shown). 245 
Our findings are in keeping with several recent studies performed in different populations of 246 
bacteraemic patients, which have not demonstrated an impact of empiric antibiotic therapy on 247 
outcome. Corona et al found no impact of empiric treatment on mortality in 1942 critical-care 248 
patients with bacteraemia (26). Anderson reported risk factors for inappropriate therapy 249 
among 1470 community-hospital bacteraemias but found no significant association with 250 
mortality (6). In a retrospective cohort study specifically in GNB bacteraemia Cain et al found an 251 
effect of empiric antibiotic therapy only among patients with a high probability of death. (28). 252 
This contrast with the older literature may reflect advances in supportive care, changes in 253 
patient mix and differences in the main antibiotic classes used.   254 
Our study has limitations. We did not confirm antibiotic susceptibilities reported by diagnostic 255 
laboratories.  However, variation between sites would not be expected to obscure an impact of 256 
antibiotic susceptibility across the whole study and should be small given that all the 257 
laboratories participate in national quality assessments and are accredited by the Royal College 258 
of Pathologists. A small number of patients were not recruited at some centres but there is no 259 
reason to think these were selected or will bias our findings.  We used mortality as our primary 260 
outcome measure and have not studied other potential harms of inappropriate antibiotic 261 
therapy such as worsening of symptoms, necessitating for example escalation of care. Another 262 
important limitation is the varying amount of missing data in baseline factors; a generic 263 
challenge in such studies.  We used multiple imputation to avoid loss of power from analyzing 264 
only (potentially unrepresentative) complete cases, a technique which is well recognised to 265 
produce unbiased estimates when missing data depend on other observed factors (including 266 
mortality), and enabling all patients to be included in multivariable models. Some potentially 267 
useful data were not collected, such as baseline albumin and rates of escalation to critical care. 268 
Our study has notable strengths. It is one of the largest prospective multi-centre studies defining 269 
the determinants of mortality specifically in GNB bacteraemia and gathered data prospectively 270 
in clinical real-time.  In line with previous recommendations [25], we have focused on empiric, 271 
as distinct from definitive therapy, accounted for the effects of confounding factors and 272 
controlled for severity of illness in our multivariable analysis.  Our data show that patient and 273 
disease factors are the primary determinants of mortality.  Antibiotic treatment algorithms for 274 
acutely unwell patients should incorporate patient factors with knowledge of local antibiotic 275 
resistance data to use broader-spectrum antibiotics for those patients who need them most. 276 
 277 
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Table 1. Baseline patient characteristics and empiric antibiotic treatment according to mortality among 679 patients with GNB bacteraemia. For each variable at each time point 
N=the number of patients for whom data were available. Percentages are column percentages and do not always add to 100% as a result of rounding. CC=complete case analysis (p-values 
from χ2 or ranksum test for categorical and continuous baseline variables) MI=multiple imputation (p-values from logistic regression adjusted for the 25 multiple imputations; imputations 
based on all 679 patients, results similar excluding from imputations nine patients who died on the day blood was taken for culture). 
 
 7-day all-cause mortality (N=679) 30-day all-cause mortality (N=674)1 
Clinical factor Survivors  
N=627 (92%) 
Non-survivors  
N=52 (8%) 
p-value (CC) p-value (MI) 
Survivors  
N=573 (85%) 
Non-survivors  
N=101 (15%) 
p-value (CC) p-value (MI) 
Gender N=626 N=51  N=572 N=100  
    Male 335 (53%) 34 (67%) 0.02 0.07 304 (53%) 62 (62%) 0.1 0.09 
Age  N=627 N=52  N=572 N=101  
     Median (IQR) 71 (58-81) 79 (69.5-83) <0.001 0.002 70 (57-81) 79 (69.5-85.5) <0.001 <0.001 
Co-morbidity score  N=617 N=49  N=564 N=97  
    Median (IQR) 6 (4-8) 7 (5-10) <0.001 0.009 6 (4-8) 7 (6-10) <0.001 <0.001 
Organism N=624 N=52  N=570 N=101  
    E. coli 409 (66%) 28 (54%) 
0.03 0.04 
375 (66%) 60 (59%) 
0.01 0.02 
    Klebsiella spp 92 (15%) 12 (23%) 86 (15%) 17 (17%) 
    Pseudomonas spp 42 (7%) 8 (15%) 35 (6%) 15 (15%) 
    Others2 81 (13%) 4 (8%) 74 (13%) 9 (9%) 
Acquisition N=614 N=49  N=561 N=97  
    Community acquired 286 (47%) 20 (42%) 
0.4 0.4 
269 (48%) 34 (35%) 
0.02 0.02     Healthcare associated 148 (24%) 10 (20%) 134 (24%) 23 (24%) 
    Nosocomial 180 (29%) 19 (39%) 158 (28%) 40 (41%) 
Focus  N=585 N=43  N=533 N=90  
    Urinary without device 223 (38%) 8 (19%) 
0.02 0.0065 
207 (39%) 22 (10%) 
<0.01 0.025 
    Urinary with device 83 (14%) 5 (12%) 75 (14%) 13 (15%) 
    Abdominal/biliary 117 (20%) 10 (23%) 107 (20%) 19 (15%) 
    Respiratory 35 (6%) 8 (19%) 28 (5%) 14 (33%) 
    Neutropenic sepsis 16 (3%) 2 (5%) 16 (3%) 2 (11%) 
    No clear source 34 (6%) 5 (12%) 30 (6%) 9 (23%) 
    Vascular device 25 (4%) 1 (2%) 23 (4%) 3 (12%) 
    Other 3 52 (9%) 4 (9%) 47 (9%) 8 (15%) 
Duration of symptoms N=471 N=23  N=435 N=55  
Symptoms post-culture only 10 (2%) - 
0.4 0.8 
7 (2%) 3 (5%)   
Same day 143 (30%) 9 (39%) 134 (31%) 15 (27%) 
0.4 0.4 
1 day 108 (23%) 4 (17%) 98 (23%) 14 (25%) 
2-4 days 137 (29%) 9 (39%) 127 (29%) 19 (35%) 
5-7 days 32 (7%) 1 (6%) 30 (7%) 2 (4%) 
>7 days 41 (9%) - 39 (9%) 2 (4%) 
Clinical disease severity          
NEWS score N=511 N=38  N=469 N=75  
   Median (IQR) 4 (2-7) 6.5 (4-9.3) <0.001 <0.001 4 (2-6) 5 (3-8) <0.001 <0.001 
WCC  N=613 N=50  N=560 N=98  
(x109/L)  Median (IQR) 11.8 (7.7-16.8) 13 (7.4-20.7) 0.5 6 11.8 (7.6-16.3) 12.6 (8-22.5) 0.08 6 
Neutrophil count  N=589 N=49  N=539 N=34  
   (x109/L)  Median (IQR) 10.4 (6.4-14.8) 10.7 (5.3-18.9) 0.8 0.5 10.3 (6.2-14.6) 11.2 (6.7-19.5) 0.09 0.002 
Platelet count N=610 N=50  N=558 N=97  
(x109/L)  Median (IQR) 196 (134-273) 191 (109-286) 0.9 0.5 198 (134-271) 179 (109-291) 0.4 0.3 
CRP  N=590 N=47  N=539 N=93  
 (mg/dL)  Median (IQR) 132 (56-205) 151 (81-287) 0.04 0.003 129 (55-202) 146 (71-261) 0.06 0.009 
Creatinine N=609 N=50  N=556 N=98  
 (μmol/L) Median (IQR) 105 (74-163) 161 (91-246) <0.001 0.037 104 (73-161) 152 (87-225) <0.001 0.047 
Initial antimicrobial therapy4  N=582 N=34  N=532 N=79  
Inappropriate 201 (35%) 9 (26%) 0.2 0.4 182 (34%) 26 (33%) 0.5 0.8 
1Data for survival at 30 days were missing for five patients who are excluded from the CC analysis, but included in the MI analysis. 2Including Morganella spp., Serratia spp., 
Enterobacter spp., Proteus spp. and Citrobacter spp. 3Including any other focus. 4Nine patients died on the day of blood culture collection and are excluded from comparisons of this 
factor; P=0.8 (7-day) and 0.6 (30-day) including these patients in MI analyses. 5Focus considered with 6 categories in multiple imputation due to small numbers in individual 
categories leading to unstable imputations (urinary, abdominal/biliary, respiratory, neutropenic sepsis, no clear source, other). 6Spearman correlation 0.96 between neutrophils 
and WCC so only neutrophils used in imputation models. 7 P=0.002 (7-day) and 0.001 (30-day) for inverse square-root transformed creatinine (the best-fitting univariable 
polynomial transformation). 
 
 
 
 
 
 
Table 2: Independent (multivariable) predictors of all cause mortality at 7- and 30-days post GNB bacteraemia by multiple 
imputation (N=670). 
 
Clinical factor 7-day all cause mortality 30-day all cause mortality 
 OR (95% CI) p-value OR (95% CI) p-value 
Age (per 10 years older) 1.54 (1.11-1.97) 0.002 1.47 (1.15-1.80) <0.001 
Charlson score (per point higher)   1.13 (1.03-1.25) 0.01 
NEWS score (per point higher) 1.26 (1.13-1.40) <0.001 1.15 (1.05-1.25) 0.002 
Neutrophil count (per 1 x 109/l higher)   1.05 (1.01-1.09) 0.009 
CRP (per 10 mg/dl higher) 1.05 (1.02-1.08) 0.003 1.03 (1.01-1.06) 0.02 
Platelet count (per 50 x 109/l higher)   0.86 (0.76- 0.97) 0.02 
Acquisition:  
Community acquired 
   
1.00 
 
    Healthcare associated   1.37 (0.70-2.70) 0.36 
    Nosocomial   2.35 (1.24-4.43) 0.008 
Focus:  
Urinary 
 
1.00 
  
1.00 
 
Abdominal/Biliary 2.07 (0.78-5.45) 0.14 1.37 (0.68-2.78) 0.38 
Respiratory 2.90 (0.89-9.43) 0.08 3.32 (1.35-8.19) 0.009 
No clear source 0.98 (0.18-5.33) 0.98 1.27 (0.42-3.81) 0.68 
Neutropenic sepsis 8.29 (1.36-50.5) 0.02 3.17 (0.56-18.1) 0.19 
Others1 2.66 (0.82-8.63) 0.10 2.05 (0.86-4.90) 0.11 
Days from symptoms to blood culture:     
Symptoms after culture only   4.69 (1.01-21.8) 0.05 
Same day   1.00  
1 day   1.34 (0.58-3.09) 0.49 
2-4 days   1.32 (0.57-3.08) 0.51 
5-7 days   0.66 (0.20-2.16) 0.49 
Empiric therapy: 
Appropriate 
 
1.00 
  
1.00 
 
Inappropriate 0.82 (0.35-1.94) 0.66 0.92 (0.50-1.66) 0.77 
Adjusted difference in the absolute percentage 
mortality between inappropriate vs appropriate 
empiric therapy (- means lower in inappropriate) 2 
 
-0.4% (-2.0%,+1.3%) 
 
-0.3% (-2.5%,+1.9%) 
1 Including any other focus. Note: Excluding nine patients who died on the day of blood culture (see Supplementary Table 2 for sensitivity 
analyses including these patients in the imputations and multivariable models). There was no independent impact on 7- or 30-day mortality 
of organism (p=0.4/0.7), gender (p=0.5/0.7), creatinine (p=0.1/0.2); and no independent impact of age-adjusted co-morbidity score (p=0.3), 
neutrophils (p=0.6), platelets (p=1.0), acquisition (p=0.6) or days of symptoms (p=0.8) on 7-day mortality. There was no evidence of 
interactions between empiric therapy and other factors for 7-day (p>0.15) or for 30-day mortality (p>0.08) except for 30-day mortality and 
neutrophils (interaction p=0.03); whereby risk of mortality at 30 days was higher in those receiving appropriate antibiotics if baseline 
neutrophils was >11, and higher in those receiving inappropriate antibiotics if baseline neutrophils was <11. 
2 Calculated from the coefficients of the regression model at the median/mode of other included factors, see supplementary material. 
Unadjusted difference in the absolute percentage mortality between inappropriate vs appropriate empiric therapy -2.0% (-6.5%,+2.4%) at 
7-days and -0.6% (-6.6%,+5.4%) at 30 days. 
 
 
